Two Sigma Investments LP Grows Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Two Sigma Investments LP grew its holdings in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 44.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 136,920 shares of the company's stock after buying an additional 41,836 shares during the period. Two Sigma Investments LP owned approximately 0.33% of Vigil Neuroscience worth $233,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the stock. Trustees of Columbia University in the City of New York purchased a new position in Vigil Neuroscience during the 4th quarter worth $328,000. Millennium Management LLC raised its holdings in Vigil Neuroscience by 23.3% during the 4th quarter. Millennium Management LLC now owns 343,814 shares of the company's stock valued at $584,000 after acquiring an additional 65,058 shares during the period. Ensign Peak Advisors Inc boosted its stake in Vigil Neuroscience by 16.1% in the 4th quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company's stock worth $1,195,000 after purchasing an additional 97,580 shares during the period. Cubist Systematic Strategies LLC grew its stake in Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after acquiring an additional 8,358 shares in the last quarter. Finally, 683 Capital Management LLC increased its holdings in shares of Vigil Neuroscience by 14.8% in the fourth quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company's stock worth $2,380,000 after purchasing an additional 180,420 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Mizuho downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. William Blair cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Jefferies Financial Group cut Vigil Neuroscience to a "hold" rating in a report on Thursday, May 22nd. JMP Securities reissued a "market perform" rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Finally, Wedbush downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and reduced their target price for the stock from $13.00 to $8.00 in a report on Thursday, May 22nd. Ten analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $10.80.

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL traded down $0.01 during midday trading on Friday, reaching $7.87. 2,999,552 shares of the stock traded hands, compared to its average volume of 714,848. The company's 50 day moving average is $3.90 and its 200 day moving average is $2.74. Vigil Neuroscience, Inc. has a one year low of $1.31 and a one year high of $7.95. The stock has a market capitalization of $367.08 million, a PE ratio of -3.82 and a beta of 3.43.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, equities analysts forecast that Vigil Neuroscience, Inc. will post -2.07 EPS for the current year.

Vigil Neuroscience Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.